Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Equillium, Inc. logo — Resetting Balance, Restoring Health

Equillium, Inc.

Resetting Balance, Restoring Health

Founded 2017 United States San Diego, United States 38 employees

General Information

Company Name Equillium, Inc.
Founded Year 2017
Location United States San Diego, United States +1
Employees 38
Social

Get notified when Equillium, Inc. moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Equillium, Inc.

Equillium is a clinical-stage biotechnology company leveraging deep understanding of immunobiology to pioneer new products with a mission to dramatically improve the lives of patients with severe autoimmune and inflammatory diseases who continue to suffer with high unmet medical needs. By bringing treatments designed to restore the balance of the immune system, we hope to restore the balance of life for patients in need. Our lead product candidate, itolizumab, is a first-in-class monoclonal antibody that targets the CD6-ALCAM signaling pathway, which plays a central role in the activation and trafficking of pathogenic effector T cells that drive inflammation in a number of diseases. We believe itolizumab may have broad therapeutic utility and our current pipeline is focused on developing itolizumab as a best-in-class treatment for multiple severe immuno-inflammatory disorders – this includes acute graft-versus-host disease, SLE / lupus nephritis and uncontrolled asthma.

No funding data available for Equillium, Inc. yet.

Get notified when Equillium, Inc. raises funding

Equillium, Inc. Alternatives & Competitors

Equillium, Inc. vs
ChemoCentryx
ChemoCentryx United States

The ChemoCentryx LinkedIn page is no longer active or monitored.

53 employees
Equillium, Inc. vs
Upstream Bio
Upstream Bio United States

Developing treatments for inflammatory diseases

IPO
78 employees
Biotechnology, Health Care
Equillium, Inc. vs
Chemomab Therapeutics
Chemomab Therapeutics Israel

Developing innovative therapeutics for diseases at confluence of fibrosis and inflammation with high...

Post Ipo Equity
21 employees
Biotechnology, Health Care

FAQ About Equillium, Inc.

Resetting Balance, Restoring Health
Equillium, Inc. was founded in 2017.
Equillium, Inc. is headquartered in San Diego, United States.
Equillium, Inc. has approximately 38 employees.
Top alternatives and competitors to Equillium, Inc. include ChemoCentryx, Upstream Bio, Chemomab Therapeutics, Tr1X, Hypo-Stream Ltd. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Equillium, Inc. and ChemoCentryx are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Equillium, Inc. and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy